Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Soligenix
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects must have a clinical diagnosis of CTCL (mycosis fungoides), Stage IA, Stage IB, or Stage IIA.
Subjects must have a minimum of three (3) evaluable, discrete lesions.
Subjects must be willing to refrain from sunbathing for the duration of the study.
You may not be if
History of sun hypersensitivity and photosensitive dermatoses including porphyria, systemic lupus erythematosus, Sjögren's syndrome, xeroderma pigmentosum, polymorphous light eruptions or radiation therapy within 30 days of enrolling.
Pregnancy or mothers who are breast feeding.
Males and females not willing to use effective contraception.
Unhealed sunburn.
Subjects receiving topical steroids or other topical treatments for CTCL within 2 weeks.
Subjects receiving systemic steroids, nitrogen mustard, psoralen UVA radiation therapy (PUVA), narrow band UVB light therapy (NB-UVB) or carmustine (BCNU) or other systemic therapies for CTCL within 3 weeks of enrollment.
Subjects with significant history of systemic immunosuppression due to drugs or infection with HIV or HTLV 1.
Subjects taking other investigational drugs or drugs of abuse within 30 days of entry into this study.
Clareo Health | FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
